SCHEMBL3520657

SCHEMBL3520657

Cc1ccc([S+](c2ccc(C)cc2)c2ccc3oc4ccccc4c(=S)c3c2)cc1.O=S(=O)([O-])C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BCAT1 P54687 1/20 0.34
MAOB P27338 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.31
TNKS O95271 1/20 0.31
PARP1 P09874 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
PARP2 Q9UGN5 1/20 0.31
ALDH1A1 P00352 1/20 0.30
CYP1A2 P05177 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
CYP2C19 P33261 1/20 0.30
HTT P42858 1/20 0.30
PIK3CD O00329 1/20 0.30
PIK3CA P42336 1/20 0.30
PIK3CB P42338 1/20 0.30
PIK3CG P48736 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519675 0.93 SMN1; SMN2 (0.32) SMN1; SMN2ALDH1A1CYP1A2GAAHPGD
SCHEMBL3520219 0.92 SMN1; SMN2 (0.32) SMN1; SMN2ALDH1A1CYP1A2GAAHPGD
Trifluoromethanesulfonic Acid SCHEMBL3519028 0.90 BCAT1 (0.38) BCAT1MAOBSMN1; SMN2TNKSPARP1
SCHEMBL3519819 0.89 NPC1 (0.40) BCAT1MAOBSMN1; SMN2TNKSPARP1
SCHEMBL3520234 0.84 BCAT1 (0.42) BCAT1MAOBSMN1; SMN2TNKSPARP1
SCHEMBL3523833 0.82 BCAT1 (0.40) BCAT1MAOBSMN1; SMN2TNKSPARP1
Trifluoromethanesulfonic Acid SCHEMBL3521317 0.82 SMN1; SMN2 (0.34) BCAT1SMN1; SMN2ALDH1A1CYP1A2GAA
SCHEMBL3521374 0.82 TTR (0.40) SMN1; SMN2ALDH1A1HPGD
SCHEMBL5044626 0.82 MAOB (0.46) BCAT1MAOBSMN1; SMN2TNKSPARP1
SCHEMBL3518429 0.81 TTR (0.39) SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7833691-B2 Heterocycle-bearing onium salts WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-11-16 US disclosed
EP-1953149-A2 A heterocycle-containing onium salt Wako Pure Chemical Industries, Ltd. (JP) 2008-08-06 EP disclosed
US-20080161520-A1 Heterocycle-bearing onium salts WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-07-03 US disclosed
US-7318991-B2 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-15 US disclosed
US-20050233253-A1 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether WAKO PURE CHEMICAL INDUSTRIES, LTD (JP) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233253-A1 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether NOX4, CBR1, CBR3 BCAT1 1269/4885MAOB 1286/4885SMN1; SMN2 4320/4885
US-20080161520-A1 Heterocycle-bearing onium salts MCM5, NIT2, PCNA BCAT1 353/4885MAOB 1248/4885SMN1; SMN2 3528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.